Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) today provided the following corporate update:
Ground-Breaking University of Alberta Study, Co-Led by AUSA CSO Dr. Jason Dyck, Confirms Opioid Sparing Effects of Medical Cannabis.
Australis Chief Science Officer Dr. Jason Dyck, the co-lead author on a peer reviewed article, is pleased to share the ground-breaking study conducted by the University of Alberta. The objective of this study was to assess the effect of medical cannabis authorization on opioid use between 2013 and 2018 in Alberta, Canada. A strong correlation was found between reduced opioid use (by heavy consumers) and the adoption of medical cannabis in pain management regimes.
The study was conducted in Canada on the largest global population of federally legal medical cannabis patients. These medically prescribed patients were tracked comparing medical cannabis use with opioid use. The importance of this study is that it strengthens the evidence that use of medical cannabis for pain management may represent an alternative to opioid medication. The results from the study are anticipated to provide the rapidly growing number of physicians willing to consider prescribing cannabis with much needed information about alternatives to pain management plans.
Dr. Dyck commented, “The findings of this study are profound in that they provide more information to physicians who are seeking to help patients reduce their dependency on opioids for pain management. This work may assist with helping clinicians combat the opioid crisis that is ongoing in our society.”
Terry Booth, CEO commented, “AUSA is proud to have Dr. Jason Dyck as our Chief Science Officer. This study supports what we have thought for many years, and in my opinion proves that cannabis is a safe alternative to opioids.”
The full article can be found here: https://pubmed.ncbi.nlm.nih.gov/33933061/
Hanoz Kapadia Appointed Chairman of the Board
The Company today announced that Mr. Hanoz Kapadia has been appointed Chairman of the Board of Directors